Merck and Hanmi Collaborate to Develop Efinopegdutide for NASH

 Merck and Hanmi Collaborate to Develop Efinopegdutide for NASH

Merck and Hanmi Collaborate to Develop Efinopegdutide for NASH

Shots:

  • Hanmi to receive $10M up front, $860M as development, regulatory approval, and commercialization of efinopegdutide along with royalties on sales of the approved product
  • Merck to receive an exclusive license to develop, manufacture and commercialize efinopegdutide in the US and globally while Hanmi to retain an option to commercialize the therapy in Korea
  • Efinopegdutide is a GLP-1/glucagon receptor dual agonist, activating the both the GLP-1 and glucagon receptors, currently being evaluated in multiple P-I & P-II studies, including for the treatment of severely obese individuals with/without T2D

Click here ­to­ read full press release/ article | Ref: Merck & Co. | Image: PharmaShots

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post